^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PV-001-DV

i
Other names: PV-001-DV, dengue virus-1 #45AZ5, PV 001-DV, PV001-DV
Associations
Company:
PrimeVax
Drug class:
Immunostimulant
Related drugs:
Associations
over1year
Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses. (PubMed, J Transl Med)
The direct in vitro tumor-killing and immune-mediated tumor cytotoxicity facilitated by PV001-DV contributes support of its upcoming clinical evaluation in patients with advanced melanoma who have failed prior therapy.
Journal • PD(L)-1 Biomarker • IO biomarker • Tumor cell
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PV-001-DV
over1year
Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
PV-001-DC • PV-001-DV
over1year
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
BRAF mutation
|
PV-001-DC • PV-001-DV
over1year
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PV-001-DC • PV-001-DV
over2years
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
BRAF mutation
|
PV-001-DC • PV-001-DV
over2years
Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
PV-001-DC • PV-001-DV
almost3years
Arm 3: Intratumoral Injection of PV-001-DV in Combination With Infusion of PV-001-DC in Patients With Advanced Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Sep 2023 --> Dec 2022 | Trial primary completion date: Jan 2023 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
PV-001-DC • PV-001-DV
almost3years
Arm 2: Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Advanced Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
BRAF mutation
|
PV-001-DC • PV-001-DV